摘要
尼莫地平作为第2代二氢吡啶类Ca2+拮抗剂,在脑血管疾病治疗上具有极大的潜力,其临床应用和研究范围正不断扩大。目前上市的剂型主要为口服或注射的普通制剂,普遍存在需多次给药、易导致机体产生不良反应及生物利用度不高等问题,因此对其新剂型的开发势在必行。本文综述了尼莫地平剂型相关研究进展,主要对现有的尼莫地平片剂、胶囊剂、注射剂、口服液等的市场现状、有效性等进行了比较,同时总结了尼莫地平新剂型的主要研究方向,为进一步开发安全、疗效可控和依从性高的新产品提供参考。
Nimodipine is the second generation of dihydropyridine Ca2 ＋antagonist. The scope of its clinical application has been expanded because of the excellent curative effects on cerebrovascular diseases. Nimodipine is commonly available on the market as oral or injection preparation,which has to be given several times per day. It may induce peripheral cholinergia side effects and has low bioavailability. Therefore,it is necessary to develop novel drug formulation with optimized delivery system. In the present review,an attempt is made to discuss the current progress of nimodipine in pharmaceutics,including the difference of market situation,safety and efficacy of different dosage forms. Meanwhile,the main research directions of new dosage forms are summarized,which can provide reference for developing more efficient and convenient nimodipine preparations.
作者
林翠翠
夏自花
杨帆
LIN Cui-cui XIA Zi-hua YANG Fan(School of Pharmacy, Guangdong Pharmaceutical College, Guangdong 510006, China)
出处
《国际药学研究杂志》
CSCD
北大核心
2017年第6期518-521,共4页
Journal of International Pharmaceutical Research
基金
广东省科技计划资助项目(201508010036
201300000046)
关键词
抗高血压药
尼莫地平
剂型
市场分析
临床应用
antihypertensive agents
nimodipine
dosage forms
marketing analysis
clinical application
